Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-07-31
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-02 (study day 3.0); relationship: PROBABLE
moderate
assessed
Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-02 (study day 3.0); relationship: PROBABLE
moderate
assessed
Moderate APPLICATION SITE VESICLES — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-05 (study day 6.0); relationship: PROBABLE
Data queries
No data queries.